share_log

S-3: Registration statement for specified transactions by certain issuers

S-3: Registration statement for specified transactions by certain issuers

S-3：特定交易注册声明
美股SEC公告 ·  09/09 12:40

Moomoo AI 已提取核心信息

Aclarion, Inc., a healthcare technology company, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on September 6, 2024. The filing indicates Aclarion's intent to offer and sell securities, including common stock, preferred stock, warrants, subscription rights, debt securities, and units, up to a total gross proceeds of $50,000,000. The securities may be offered from time to time in one or more series, and the proceeds are intended for market development, clinical evidence, product development, general administration support, and other corporate purposes. Aclarion's common stock is quoted on the Nasdaq Capital Market under the symbol 'ACON.' The company has also detailed its indemnification policy for directors and officers, stating that it will provide mandatory indemnification to the fullest extent permitted by law. The registration statement includes various legal and financial documents, such as the company's bylaws, certificate of incorporation, and financial statements audited by Haynie & Company and CohnReznick LLP.
Aclarion, Inc., a healthcare technology company, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on September 6, 2024. The filing indicates Aclarion's intent to offer and sell securities, including common stock, preferred stock, warrants, subscription rights, debt securities, and units, up to a total gross proceeds of $50,000,000. The securities may be offered from time to time in one or more series, and the proceeds are intended for market development, clinical evidence, product development, general administration support, and other corporate purposes. Aclarion's common stock is quoted on the Nasdaq Capital Market under the symbol 'ACON.' The company has also detailed its indemnification policy for directors and officers, stating that it will provide mandatory indemnification to the fullest extent permitted by law. The registration statement includes various legal and financial documents, such as the company's bylaws, certificate of incorporation, and financial statements audited by Haynie & Company and CohnReznick LLP.
医疗科技公司Aclarion, Inc.于2024年9月6日向美国证券交易委员会（SEC）提交了S-3登记申请文件。这一申请表明Aclarion有意以总额为$50,000,000的总毛收入的方式发行和销售证券，包括普通股、优先股、认股权证、认购权证、债务证券和单位。这些证券可能会分别或同时以一个或多个系列的方式进行发行，所得收益将用于市场开发、临床证据、产品开发、一般行政支持和其他公司用途。Aclarion的普通股在纳斯达克资本市场上以ACON作为标的进行报价。公司还详细说明了董事和高级管理人员的赔偿政策，称将在法律允许的最大限度上提供强制性赔偿。登记申请文件包括各种法律和财务文件，如公司的章程、公司证书和由Haynie & Company和CohnReznick LLP审计的财务报表。
医疗科技公司Aclarion, Inc.于2024年9月6日向美国证券交易委员会（SEC）提交了S-3登记申请文件。这一申请表明Aclarion有意以总额为$50,000,000的总毛收入的方式发行和销售证券，包括普通股、优先股、认股权证、认购权证、债务证券和单位。这些证券可能会分别或同时以一个或多个系列的方式进行发行，所得收益将用于市场开发、临床证据、产品开发、一般行政支持和其他公司用途。Aclarion的普通股在纳斯达克资本市场上以ACON作为标的进行报价。公司还详细说明了董事和高级管理人员的赔偿政策，称将在法律允许的最大限度上提供强制性赔偿。登记申请文件包括各种法律和财务文件，如公司的章程、公司证书和由Haynie & Company和CohnReznick LLP审计的财务报表。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间